A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
- Conditions
- Multiple Myeloma (MM)Cancer
- Interventions
- Drug: ABBV-467
- Registration Number
- NCT04178902
- Lead Sponsor
- AbbVie
- Brief Summary
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 8
-
Documented diagnosis of multiple myeloma (MM).
-
Measurable disease defined as at least 1 of the following:
- Serum monoclonal protein >= 1g/dL.
- Urine M-protein >= 200mg/24 hours.
- Serum immunoglobulin free light chain (FLC) >= 10 mg/dL (100 mg/L), provided serum FLC ratio is abnormal.
-
Relapsed after or are refractory or intolerant to all established MM therapies that are both known to provide clinical benefit and locally available.
-
Received at least 3 prior lines of therapy including 1 or more immunomodulatory agents, 1 or more proteasome inhibitors, and 1 or more anti-CD38 monoclonal antibodies.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
-
Adequate hematologic, renal and hepatic function as described in the protocol.
-
Echocardiogram with ejection fraction >= 50% and no other clinically significant findings that would increase the participant's susceptibility to cardiac toxicity.
- Prior exposure to any targeted myeloid cell leukemia-1 (MCL-1) inhibitor.
- Antineoplastic therapy (including any cytotoxic, targeted and/or investigational therapy; but not including corticosteroids), within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug and through the last dose of study drug.
- Autologous stem cell transplant within 90 days prior to start of study drug.
- Allogenic stem cell transplant within 180 days prior to start of study drug.
- History of acute or chronic pancreatitis.
- Significant unresolved liver disease.
- History of hepatitis B or human immunodeficiency virus (HIV) infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part A: ABBV-467 Dose Escalation ABBV-467 ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined. Part B: ABBV-467 Dose Expansion ABBV-467 ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
- Primary Outcome Measures
Name Time Method Number of Participants with Adverse Events Up to approximately 24 months after first dose of study drug An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator will assess the relationship of each event to the use of study drug as being of reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
Change in Vital Signs Baseline (Week 0) through approximately 24 months after first dose of study drug Change in vital signs like systolic and diastolic blood pressure will be assessed.
Change in Electrocardiogram (ECG) Baseline (Week 0) through approximately 24 months after first dose of study drug 12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.
Change in Cardiac Enzyme Levels Baseline (Week 0) through approximately 24 months after first dose of study drug Change in cardiac enzyme levels will be recorded.
Incidence of Abnormal Clinical Laboratory Test Results Baseline (Week 0) through approximately 24 months after first dose of study drug Number of participants with incidence of abnormal clinical laboratory test results like hematology will be assessed.
Maximum Observed Plasma Concentration (Cmax) Up to approximately Day 197 Maximum Plasma Concentration (Cmax) of ABBV-467.
Terminal Phase Elimination Half-life (t1/2) Up to approximately Day 197 Terminal phase elimination half-life (t1/2) of ABBV-467
Area Under the Plasma Concentration-Time Curve (AUCt) Up to approximately Day 197 AUC from time 0 to time of last measurable concentration of ABBV-467.
Area Under the Plasma Concentration-Time Curve (AUC0-infinity) Up to approximately Day 197 AUC from time 0 to infinity of ABBV-467.
Clearance of ABBV-467 Up to approximately Day 197 Clearance of ABBV-467.
- Secondary Outcome Measures
Name Time Method Overall Response Rate (ORR) Up to approximately 24 months after first dose of study drug ORR evaluated per adapted International Myeloma Working Group (IMWG) criteria and defined as partial response (PR) + very good partial response (VGPR) + complete remission (CR) + stringent complete response (sCR).
Clinical Benefit Rate (CBR) Up to approximately 24 months after first dose of study drug CBR evaluated per adapted International Myeloma Working Group (IMWG) criteria and is defined as minimal response (MR) + PR + VGPR + CR + sCR.
Duration of Response (DOR) Up to approximately 24 months after first dose of study drug DOR is defined as the time between date of first response and the first occurrence of progression or death from any cause, whichever comes first.
Trial Locations
- Locations (24)
Royal Adelaide Hospital /ID# 223354
🇦🇺Adelaide, South Australia, Australia
Royal Perth Hospital /ID# 225498
🇦🇺Perth, Western Australia, Australia
Perth Blood Institute Ltd /ID# 226650
🇦🇺Nedlands, Western Australia, Australia
Alfred Health /ID# 214665
🇦🇺Melbourne, Victoria, Australia
University of Arizona Cancer Center - North Campus /ID# 219102
🇺🇸Tucson, Arizona, United States
Hackensack Univ Med Ctr /ID# 221035
🇺🇸Hackensack, New Jersey, United States
Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418
🇺🇸Providence, Rhode Island, United States
Prisma Health Cancer Institute-Faris Road /ID# 219076
🇺🇸Greenville, South Carolina, United States
City of Hope /ID# 209786
🇺🇸Duarte, California, United States
St Vincent's Hospital Melbourne /ID# 222066
🇦🇺Fitzroy, Victoria, Australia
Hopital Henri Mondor /ID# 214588
🇫🇷Creteil, France
CHU de Nantes, Hotel Dieu -HME /ID# 215480
🇫🇷Nantes, Pays-de-la-Loire, France
Sheba Medical Center /ID# 214065
🇮🇱Ramat Gan, Tel-Aviv, Israel
Nagoya City University Hospital /ID# 214696
🇯🇵Nagoya shi, Aichi, Japan
National Cancer Center Hospital East /ID# 214697
🇯🇵Kashiwa-shi, Chiba, Japan
CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 217170
🇪🇸Pamplona, Navarra, Comunidad, Spain
National Cancer Center Hospital /ID# 214801
🇯🇵Chuo-ku, Tokyo, Japan
Kyushu University Hospital /ID# 220800
🇯🇵Fukuoka-shi, Fukuoka, Japan
Hospital Universitario Vall d'Hebron /ID# 214690
🇪🇸Barcelona, Spain
CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 214739
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz /ID# 214672
🇪🇸Madrid, Spain
Hospital Universitario Virgen de la Victoria /ID# 214756
🇪🇸Malaga, Spain
China Medical University Hosp /ID# 209323
🇨🇳Taichung City, Taiwan
National Taiwan University Hospital /ID# 209322
🇨🇳Taipei City, Taipei, Taiwan